NCT05731999 is a NA clinical trial of Previct Drugs in Drug Abuse, sponsored by Kontigo Care AB.

Who is sponsoring NCT05731999?

NCT05731999 is sponsored by Kontigo Care AB.

What drugs are being tested in NCT05731999?

Interventions in NCT05731999: Previct Drugs.

What condition does NCT05731999 study?

NCT05731999 studies Drug Abuse.

Is NCT05731999 still recruiting?

NCT05731999 is currently completed. Last updated 2 April 2025.

Are results published for NCT05731999?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-04-02 · How we verify

NCT05731999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First Study in Healthy Volunteers of a New Mobile Phone Application Measuring the Eyes Before and After Medication

Completed NA Results posted Last updated 2 April 2025

What this trial tests

NA trial testing Previct Drugs in Drug Abuse in 48 participants. Completed in 19 July 2023.

Timeline

15 February 2023

Primary endpoint
19 July 2023

19 July 2023

Quick facts

Lead sponsor	Kontigo Care AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	48
Start date	15 February 2023
Primary completion	19 July 2023
Estimated completion	19 July 2023
Sites	1 location across Netherlands

Drugs / interventions tested

Previct Drugs

Conditions studied

Drug Abuse — all drugs for Drug Abuse →

Sponsor

Kontigo Care AB

Who can join

Adults 18 to 70, any sex, with Drug Abuse. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Use of Self-administered Pupillometry Using a Mobile Phone Application Can be Used to Collect Pupillograms Before and Under the Influence of Phenethylamines, Benzodiazepines, Cannabinoids, and Opioids (D1-D4). Primary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), the fraction of collected pupillometry data from the mobile phone application at baseline and under the influence of D1-D4, which can be transformed into pre-defined key features using native pupillogram. A key feature represents an eye characteristic (such as pupil size, iris position, and the similar). A successful transformation is characterised by underlying quality control algorithms approving the extracted magnitude, where poor quality pupillograms are rejected from analysis. Each attempt to transform a pupillogram into key features is denoted an "Atte

Successful attempts - Non-convergence (NC)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	295
Single Application of Benzodiazepines (D2)	286
Single Application of Cannabinoids (D3)	317
Single Application of Opioids (D4)	300

Successful attempts - Horizontal nystagmus (NY)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	279
Single Application of Benzodiazepines (D2)	242
Single Application of Cannabinoids (D3)	300
Single Application of Opioids (D4)	282

Successful attempts - Tremor (TR)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	295
Single Application of Benzodiazepines (D2)	282
Single Application of Cannabinoids (D3)	319
Single Application of Opioids (D4)	295

Successful attempts - Pupillary light reflex (PLR)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	290
Single Application of Benzodiazepines (D2)	297
Single Application of Cannabinoids (D3)	302
Single Application of Opioids (D4)	307

Successful attempts - Redness (RED)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	314
Single Application of Benzodiazepines (D2)	317
Single Application of Cannabinoids (D3)	312
Single Application of Opioids (D4)	325

Use of Self-administered Pupillometry Using a Mobile Phone Application, After Refining the Method for Establishing Pupillograms, Can be Used to Collect Pupillograms Before and Under the Influence of Each Medicinal Product (D1-D4). Secondary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), the fraction of collected pupillometry data from the mobile phone application at baseline and under the influence of D1-D4, which can be transformed into pre-defined key features using refined pupillogram. A key feature represents an eye characteristic (such as pupil size, iris position, and the similar). A successful transformation is characterised by underlying quality control algorithms approving the extracted magnitude, where poor quality pupillograms are rejected from analysis. Each attempt to transform a pupillogram into key features is denoted an "Att

Successful attempts - Non-convergence (NC)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	296
Single Application of Benzodiazepines (D2)	282
Single Application of Cannabinoids (D3)	318
Single Application of Opioids (D4)	297

Successful attempts - Horizontal nystagmus (NY)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	281
Single Application of Benzodiazepines (D2)	241
Single Application of Cannabinoids (D3)	305
Single Application of Opioids (D4)	281

Successful attempts - Tremor (TR)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	295
Single Application of Benzodiazepines (D2)	282
Single Application of Cannabinoids (D3)	319
Single Application of Opioids (D4)	295

Successful attempts - Pupillary light reflex (PLR)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	294
Single Application of Benzodiazepines (D2)	303
Single Application of Cannabinoids (D3)	309
Single Application of Opioids (D4)	317

Successful attempts - Redness (RED)

Group	Value	95% CI
Single Application of Phenethylamines (D1)	314
Single Application of Benzodiazepines (D2)	317
Single Application of Cannabinoids (D3)	312
Single Application of Opioids (D4)	325

Number of Key Features With Change From Baseline to Peak Concentration in Plasma, Using Refined Pupillograms. Secondary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), number of changed key features from baseline to the LC-MS/MS (Liquid Chromatography Tandem Mass-Spectroscopy) verified peak concentration in plasma after administration of medicinal product at visit 2 using refined pupillograms. Each of the 24 key features represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "changed" if the difference between averages at baseline and peak concentration is significant (p\<0.05). Key features were available from two conditions, one condition where pupillograms and

50 Lux

Group	Value	95% CI
Single Application of Phenethylamines	5
Single Application of Benzodiazepines	1
Single Application of Cannabinoids	4
Single Application of Opioids	7

500 Lux

Group	Value	95% CI
Single Application of Phenethylamines	5
Single Application of Benzodiazepines	3
Single Application of Cannabinoids	2
Single Application of Opioids	7

Number of Key Features for Which Correlation Between Pupillometric Variables and Concentration in Plasma Over Time is Significant for Each Medicinal Product D1-D4 and Ambient Light Condition. Secondary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), number of significant correlations between key features and plasma concentration over time using refined pupillograms. A key feature represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "correlated" if the slope in a linear regression is significantly different from zero (p\<0.05). The term correlated over time refers to data collected during 5 hours at Visit 2 after administration of D1-D4. Key features were available from two conditions, one condition where pupillograms and corresponding key fea

50 LUX

Group	Value	95% CI
Single Application of Phenethylamines	5
Single Application of Benzodiazepines	6
Single Application of Cannabinoids	7
Single Application of Opioids	10

500 LUX

Group	Value	95% CI
Single Application of Phenethylamines	7
Single Application of Benzodiazepines	4
Single Application of Cannabinoids	2
Single Application of Opioids	9

Number of Key Features With Change From Baseline to 5 Hours After Administration of Medicinal Product, Using Refined Pupillograms. Secondary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), number of changed key features from baseline to 5 hours after administration of medicinal product at visit 2 using refined pupillograms. A key feature represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "changed" if the difference between averages at baseline and at 5 hours is significant (p\<0.05). Key features were available from two conditions, one condition where pupillograms and corresponding key features were collected in dim ambient light (50 Lux) and one condition where pupillograms and c

50 LUX

Group	Value	95% CI
Single Application of Phenethylamines	6
Single Application of Benzodiazepines	1
Single Application of Cannabinoids	2
Single Application of Opioids	8

500 LUX

Group	Value	95% CI
Single Application of Phenethylamines	5
Single Application of Benzodiazepines	5
Single Application of Cannabinoids	0
Single Application of Opioids	6

Number of Correct Classifications of Subjects, Evaluated Using a Combination of Different Pupillometric Variables for Indicating Use of Each Medicinal Product D1-D4 and Ambient Light Condition. Secondary · Day 7 +/- 2 days (Visit 2)

For each medicinal product (D1-D4), evaluate known combinations of key features that changes from baseline to the LC-MS/MS verified peak concentration in plasma after administration of medicinal product at visit 2 using refined pupillograms. A key feature represents an eye characteristic (such as pupil size, iris position, and the similar). A combination of key features collected at peak plasma concentration was used to build a logistic regression classifier, and the resulting counts of true positives, true negatives, false positives, and false negatives are presented. Key features were availa

At baseline number of true negative

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	12
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	12
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	12
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	10
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	11
Single Application of Cannabinoids - 50 Lux Key Feature MCA	12
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	12
Single Application of Cannabinoids - 500 Lux Key Feature Redness	12
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	11
Single Application of Opioids - 50 Lux Key Feature Dbase	12
Single Application of Opioids - 500 Lux Key Feature Dbase	11

At baseline number of false positive

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	0
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	0
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	2
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	1
Single Application of Cannabinoids - 50 Lux Key Feature MCA	0
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	1
Single Application of Opioids - 50 Lux Key Feature Dbase	0
Single Application of Opioids - 500 Lux Key Feature Dbase	0

At baseline, missing key feature data

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	0
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	0
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	0
Single Application of Cannabinoids - 50 Lux Key Feature MCA	0
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	0
Single Application of Opioids - 50 Lux Key Feature Dbase	0
Single Application of Opioids - 500 Lux Key Feature Dbase	1

At peak concentration number of true positive

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	12
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	12
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	12
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	11
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	10
Single Application of Cannabinoids - 50 Lux Key Feature MCA	10
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	11
Single Application of Cannabinoids - 500 Lux Key Feature Redness	8
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	9
Single Application of Opioids - 50 Lux Key Feature Dbase	12
Single Application of Opioids - 500 Lux Key Feature Dbase	11

At peak concentration number of false negative

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	0
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	0
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	1
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	1
Single Application of Cannabinoids - 50 Lux Key Feature MCA	1
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness	3
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	1
Single Application of Opioids - 50 Lux Key Feature Dbase	0
Single Application of Opioids - 500 Lux Key Feature Dbase	0

At peak concentration, missing key feature data

Group	Value	95% CI
Single Application of Phenethylamines - 50 Lux Key Feature Dbase	0
Single Application of Phenethylamines - 500 Lux Key Feature Dbase	0
Single Application of Benzodiazepines - 50 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff	0
Single Application of Benzodiazepines - 500 Lux Key Feature NCdiff-NYave	1
Single Application of Cannabinoids - 50 Lux Key Feature MCA	1
Single Application of Cannabinoids - 50 Lux Key Feature MCA + Redness	1
Single Application of Cannabinoids - 500 Lux Key Feature Redness	0
Single Application of Cannabinoids - 500 Lux Key Feature Redness+NYNumber	2
Single Application of Opioids - 50 Lux Key Feature Dbase	0
Single Application of Opioids - 500 Lux Key Feature Dbase	1

Usability Questionnaire - Question 1 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 1. How would you grade the instructions for use? Response options: * Not understandable * Could only understand some parts * Could understand most parts * Could understand almost every part * Fully understandable

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	1
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0
Healthy Volunteers With Single Application of Phenethylamines (D1)	1
Healthy Volunteers With Single Application of Benzodiazepines (D2)	5
Healthy Volunteers With Single Application of Cannabinoids (D3)	5
Healthy Volunteers With Single Application of Opioids (D4)	3

Usability Questionnaire - Question 2 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 2. Was Previct Drugs easy to use correctly based on the information in the Instructions For Use (IFU)? Response options: * Yes * No

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	11
Healthy Volunteers With Single Application of Benzodiazepines (D2)	12
Healthy Volunteers With Single Application of Cannabinoids (D3)	12
Healthy Volunteers With Single Application of Opioids (D4)	12
Healthy Volunteers With Single Application of Phenethylamines (D1)	1
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0

Usability Questionnaire - Question 4 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 4. How did you experience the verbal instructions during a test with Previct Drugs? Response options: * Very easy to understand * Easy to understand * Nor easy or difficult to understand * Difficult to understand * Very difficult to understand

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	11
Healthy Volunteers With Single Application of Benzodiazepines (D2)	8
Healthy Volunteers With Single Application of Cannabinoids (D3)	5
Healthy Volunteers With Single Application of Opioids (D4)	6
Healthy Volunteers With Single Application of Phenethylamines (D1)	1
Healthy Volunteers With Single Application of Benzodiazepines (D2)	4
Healthy Volunteers With Single Application of Cannabinoids (D3)	7
Healthy Volunteers With Single Application of Opioids (D4)	6
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0

Usability Questionnaire - Question 5 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 5. Before starting a test, the App prompted you with a few written instructions. Did you read the instructions? Response options: * Yes * No

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	12
Healthy Volunteers With Single Application of Benzodiazepines (D2)	10
Healthy Volunteers With Single Application of Cannabinoids (D3)	9
Healthy Volunteers With Single Application of Opioids (D4)	11
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	2
Healthy Volunteers With Single Application of Cannabinoids (D3)	3
Healthy Volunteers With Single Application of Opioids (D4)	1

Usability Questionnaire - Question 7 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 7. How did you experience performing a test with Previct Drugs (from opening of the App until the test was completed)? Response options: * Very easy to perform * Easy to perform * Nor easy or difficult to perform * Difficult to perform * Very difficult to perform

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	5
Healthy Volunteers With Single Application of Benzodiazepines (D2)	5
Healthy Volunteers With Single Application of Cannabinoids (D3)	5
Healthy Volunteers With Single Application of Opioids (D4)	4
Healthy Volunteers With Single Application of Phenethylamines (D1)	7
Healthy Volunteers With Single Application of Benzodiazepines (D2)	5
Healthy Volunteers With Single Application of Cannabinoids (D3)	5
Healthy Volunteers With Single Application of Opioids (D4)	8
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	2
Healthy Volunteers With Single Application of Cannabinoids (D3)	2
Healthy Volunteers With Single Application of Opioids (D4)	0
Healthy Volunteers With Single Application of Phenethylamines (D1)	0
Healthy Volunteers With Single Application of Benzodiazepines (D2)	0
Healthy Volunteers With Single Application of Cannabinoids (D3)	0
Healthy Volunteers With Single Application of Opioids (D4)	0

Usability Questionnaire - Question 8 Secondary · Day 7 +/- 2 days (Visit 2)

User-friendliness of Previct Drugs evaluated by the subject at visit 2. Question 8. During a test with Previct Drugs, did you at any time have to tilt the mobile against something to be able to perform a measurement? Response options: * Yes * No

Group	Value	95% CI
Healthy Volunteers With Single Application of Phenethylamines (D1)	4
Healthy Volunteers With Single Application of Benzodiazepines (D2)	3
Healthy Volunteers With Single Application of Cannabinoids (D3)	4
Healthy Volunteers With Single Application of Opioids (D4)	4
Healthy Volunteers With Single Application of Phenethylamines (D1)	8
Healthy Volunteers With Single Application of Benzodiazepines (D2)	9
Healthy Volunteers With Single Application of Cannabinoids (D3)	8
Healthy Volunteers With Single Application of Opioids (D4)	8

Adverse events — posted to ClinicalTrials.gov

Time frame: From signed informed consent to study completion, an average of 10 days.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Healthy Volunteers With Single Application of Phenethylamines (D1)

Serious: 0/12 (0%)

Deaths: 0/48

Healthy Volunteers With Single Application of Benzodiasepines (D2)

Serious: 0/12 (0%)

Deaths: 0/12

Healthy Volunteers With Single Application of Cannabinoids (D3)

Serious: 0/12 (0%)

Deaths: 0/12

Healthy Volunteers With Single Application of Opioids (D4)

Serious: 0/12 (0%)

Deaths: 0/12

Other adverse events (7 terms — click to expand)

Reaction	System	Healthy Volunteers With Si…	Healthy Volunteers With Si…	Healthy Volunteers With Si…	Healthy Volunteers With Si…
Nausea	Nervous system disorders	—	—	—	—
Sleepiness	Investigations	—	—	—	—
Double vision	Eye disorders	—	—	—	—
Light headed, dizzy	Nervous system disorders	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
Vasovagal reaction	Nervous system disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—

Data from ClinicalTrials.gov NCT05731999 adverse events section.

Sponsor's own description

This is a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data on the medical device Previct Drugs.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers.
Kuijpers KWK, Andersson K, Winkvist M, Niesters M, et al · · 2024 · cited 4× · PMID 39840007 · DOI 10.3389/fnins.2024.1492246
Opioid Detection Using Smartphone-Based Eye-Scanning.
Kuijpers KWK, Andersson K, Dahan A, Hämäläinen MD, et al · · 2025 · PMID 40942896 · DOI 10.3390/s25175467
Detecting benzodiazepine use through induced eye convergence inability with a smartphone app: a proof-of-concept study.
Kuijpers KWK, Hämäläinen MD, Zetterström A, Winkvist M, et al · · 2025 · PMID 40520217 · DOI 10.3389/fdgth.2025.1584716

Verify or expand the search:

Other trials of Previct Drugs

Trials testing the same drug.

NCT05737550 — An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD · NA · completed

Other recruiting trials for Drug Abuse

Currently open trials in the same condition.

NCT06134882 — OUD Smartphone Services · NA · active not recruiting
NCT05918601 — Peer-led Personalized Support Program · NA · recruiting
NCT05818384 — Wakaya: Rising Up for Choctaw Youth Health · NA · recruiting
NCT05877742 — AA on Drug Abusers by Nursing Students · NA · recruiting
NCT04822987 — Factors Predicting Outcome in Group Treatment of Alcohol Use Disorders (AUDs) · active not recruiting

Other Kontigo Care AB trials

Trials by the same sponsor.

NCT06629740 — A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication · NA · completed
NCT05737550 — An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD · NA · completed
NCT03195894 — Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05731999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kontigo Care AB
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05731999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT05731999

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Previct Drugs

Other recruiting trials for Drug Abuse

Other Kontigo Care AB trials

Verify against primary sources